Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers

Arbutus Biopharma Corp

Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.
Late-breaking posters will show IM-PROVE I and IM-PROVE II Phase 2a trial data.
Immune biomarker profiling in subjects treated with imdusiran + pegylated interferon reveals phases of immune activation linked to HBsAg seroconversion.
Imdusiran target site is highly conserved across HBV genotypes A-E; SNPs do not affect HBsAg decline.
Posters will be available on Arbutus website from November 15, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.